Severe Thrombocytopenia Due to Intravenous Tirofiban Therapy

Patti, Ravikaran; Sinha, Ankur; Rodríguez, Daniel; Khanijao, Suchit; Topi, Bernard; Somal, Navjot

doi:10.1097/00045391-900000000-98490

Search citation statements

Order By: Relevance

Paper Sections

Select...

Time1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2020

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Glycoprotein IIb/IIIa inhibitors can cause drug induced thrombocytopenia, and previous case reports have been published [6][7][8][9][10]. Platelet counts less than 100 × 10^9/L occurred in 1.1 to 1.9% of patients in clinical trials of tirofiban, and counts less than 50 × 10^9/L occurred in 0.2% to 0.5% of patients [11].…”

Section: Timementioning

confidence: 94%

Rapid-Onset Thrombocytopenia Following Tirofiban Administration

M¹,

G²,

J³

2020

Int J Clin Cardiol

View full text Add to dashboard Cite

Thrombocytopenia, defined as a platelet count less than 150 × 10^9/L, has a broad differential of causes and can lead to life threatening complications. We present a case of rapid thrombocytopenia following an Aggrastat (tirofiban) bolus. The platelet count decreased from 195 × 10^9/L at the time of admission to 18 × 10^9/L. After discontinuing tirofiban, the platelet count increased to 95 × 10^9/L within several hours. PF-4 antibody and serotonin release assay testing for potential heparin induced thrombocytopenia were negative. This case highlights the importance of close monitoring of the platelet count with tirofiban administration. Medical professionals should remain aware of causes for acute thrombocytopenia in the coronary care unit and their management.

show abstract